Elon Musk is tweeting again.
The mercurial and Twitter-obsessed Tesla ($TSLA) CEO changed his handle overnight to "Elon Tusk" with an elephant emoji, and tweeted that there would be "some Tesla news" coming at 2 p.m. on Thursday.
A master of capturing media attention, Musk could be teasing a gimmicky Tesla feature, à la "Dog Mode," that would deflect some of the scrutiny he is once again under for tangling with the SEC over its regulatory practices. Or he could make a more serious announcement related to Model 3 production targets, or even how the company plans to pay off a $920 million convertible bond due on the first of the month.
The point is: no one knows ー and that's the problem. Earlier this week the SEC complained that Musk should be held in contempt for continuing to tweet market-moving investor information without prior sign-off from Tesla lawyers, which was part of Musk's settlement agreement with the agency.
That became infinitely more difficult when the company's general counsel quit last week after just two months.
Conditions have been mostly nice for travelers flying ahead of and on Christmas Day, but some naughty disruptions plagued those flying with Southwest Airlines again this year.
Gift cards make great stocking stuffers — just as long as you don't stuff them in a drawer and forget about them after the holidays.
Big Business This Week is a guided tour through the biggest market stories of the week, from winning stocks to brutal dips to the facts and forecasts generating buzz on Wall Street.
Bristol Myers Squibb agreed to buy schizophrenia drug maker Karuna Therapeutics in a $14 billion deal.
Supermarket chain Ralphs is facing a new lawsuit from the state of California.
Shake Shack is giving out free fried chicken sandwiches, bacon cheese fries and milkshakes nationwide.
The IRS is announcing a voluntary disclosure program.
Lionsgate announced its studio division is going to spin off in a merger with Screaming Eagle Acquisition Corp., which is a special purpose acquisition company.
A new report suggests that it's getting more difficult for an average American to afford a home.
The Food and Drug Administration warned consumers about a copycat version of the diabetes drug Ozempic.
